Stéphanie Romand
The Vaccine Formulation Institute (VFI) was founded in Switzerland in 2012. With the support of the World Health Organization, the European Commission, the Bill & Melinda Gates Foundation and several other stakeholders, VFI’s mission is to provide clinically relevant adjuvants under open-access terms, perform research and preclinical development of adjuvanted vaccines, and disseminate training and vaccine formulation know-how for the benefit of the entire vaccine community. VFI’s team works across several sites including two state-of-the art laboratories in Geneva and Lausanne and possesses expertise in adjuvanted vaccine R&D, adjuvant GMP manufacture and support for the clinical development of adjuvanted vaccine candidates. In the BAXERNA project VFI will develop specific analytical methods for quantifying the lipid components of candidate mRNA vaccines and assessing their chemical stability.
Stéphanie Romand
Gerben Marsman
The Vaccine Formulation Institute (VFI) was founded in Switzerland in 2012. With the support of the World Health Organization, the European Commission, the Bill & Melinda Gates Foundation and several other stakeholders, VFI’s mission is to provide clinically relevant adjuvants under open-access terms, perform research and preclinical development of adjuvanted vaccines, and disseminate training and vaccine formulation know-how for the benefit of the entire vaccine community. VFI’s team works across several sites including two state-of-the art laboratories in Geneva and Lausanne and possesses expertise in adjuvanted vaccine R&D, adjuvant GMP manufacture and support for the clinical development of adjuvanted vaccine candidates. In the BAXERNA project VFI will develop specific analytical methods for quantifying the lipid components of candidate mRNA vaccines and assessing their chemical stability.